Aroa BiosurgeryAROAF +35.24%39 Shareholder Yield % is 0.14% as of Mar. 2026, which is 40% above its 10-year median of 0.10. GuruFocus rates AROAF with a GF Score™ of 39/100 and a GF Value™ of $0.71 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 818 Medical Devices & Instruments companies, Aroa Biosurgery ranks worse than 50.12% on this metric.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return.
As of today, Aroa Biosurgery's Shareholder Yield % was 0.14%.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."
Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.
Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.
Aroa Biosurgery Shareholder Yield % Related Terms
Aroa Biosurgery Shareholder Yield % Historical Data
* Premium members only.
The historical data trend for Aroa Biosurgery's Shareholder Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AROAF vs ABT, SYK, MDT: Shareholder Yield % Comparison
For the Medical Devices subindustry, Aroa Biosurgery's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aroa Biosurgery Shareholder Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Aroa Biosurgery's Shareholder Yield % distribution charts can be found below:
* The bar in red indicates where Aroa Biosurgery's Shareholder Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
Aroa Biosurgery (AROAF) has a Shareholder Yield % of 0.14% as of Mar. 2026. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Aroa Biosurgery and its competitors. This is 40% above median its historical median of 0.10. According to the industry distribution chart, Aroa Biosurgery ranks #410 out of 818 companies in the Medical Devices & Instruments industry, placing it in the top 50.1%.
Is Aroa Biosurgery's Shareholder Yield % too high?
Aroa Biosurgery's current Shareholder Yield % of 0.14% is 40% above median its 10-year median of 0.10. The Medical Devices & Instruments industry median Shareholder Yield % is 0.16. Aroa Biosurgery's value of 0.14% is 9.7% below this industry median. Based on the distribution chart, Aroa Biosurgery ranks #410 out of 818 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Aroa Biosurgery has a GF Score™ of 39/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aroa Biosurgery's Shareholder Yield % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Aroa Biosurgery ranks #410 out of 818 companies for Shareholder Yield %. This places Aroa Biosurgery in the lower half of its industry. The industry median Shareholder Yield % is 0.16. Aroa Biosurgery's value of 0.14% is 9.7% below this benchmark. While the company's 10-year median is 0.10 vs. the industry median of 0.16, Aroa Biosurgery has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Medical Devices & Instruments company?
The median Shareholder Yield % among Medical Devices & Instruments companies is 0.16, based on 818 companies in the industry. Companies in the top quartile (top 25%) have a Shareholder Yield % significantly above this median, while those in the bottom quartile fall well below. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aroa Biosurgery's current Shareholder Yield % of 0.14% is 9.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Aroa Biosurgery and its competitors. For the Medical Devices & Instruments industry, the median Shareholder Yield % is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aroa Biosurgery's current Shareholder Yield % is 0.14%, which is 40% above median its own 10-year median of 0.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aroa Biosurgery stock overvalued right now?
Based on GuruFocus' analysis, Aroa Biosurgery (AROAF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.71, compared to a current price of $0.52 — trading 26.8% below its estimated fair value. The current Shareholder Yield % is 0.14%, which is 40% above median its 10-year median of 0.10 and 9.7% below the Medical Devices & Instruments industry median of 0.16. Aroa Biosurgery's overall GF Score™ is 39/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For Aroa Biosurgery (AROAF), the current Shareholder Yield % is 0.14% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aroa Biosurgery (AROAF) Overvalued in 2026?
Based on GuruFocus' analysis, Aroa Biosurgery stock appears to be undervalued.
The current stock price of $0.52 is trading 26.8% below its estimated GF Value™ of $0.71.
GuruFocus considers Aroa Biosurgery to be Modestly Undervalued.
Key valuation signals for AROAF:
Shareholder Yield %: 0.14% (40% above median its 10-year median of 0.10)
GF Value™: $0.71 vs. price of $0.52 (26.8% below fair value)
Industry Position: 9.7% below the Medical Devices & Instruments median (#410 of 818)
No single metric tells the full story. See the AROAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aroa Biosurgery Ltd is a soft tissue regeneration company that develops, manufactures, and sells medical devices for wound and soft tissue repair using its proprietary extracellular matrix (ECM) technology. It is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. The company is in the business of developing, manufacturing, and selling soft tissue repair products. The company's principal market is the United States, where it has five key products for sale targeting chronic wounds, hernia, plastics, reconstructive surgery, and trauma/limb salvage/tumor surgery.
39GF Score
Get the complete analysis for AROAF
Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AROAF has been successfully added to your 
